MDSpire - Takeaway
From the Journals

Low-Dose Apixaban Cuts Superficial Thrombosis Risk

Extended anticoagulation lowered symptomatic superficial vein thrombosis in patients with provoked venous thromboembolism.

Share

  • 1

    HI-PRO trial showed apixaban reduced superficial vein thrombosis.

  • 2

    Participants had undergone prior anticoagulation.

  • 3

    1.3% vs 4.3% symptomatic events with apixaban vs placebo.

  • 4

    Secondary outcomes were not statistically significant.

  • 5

    Need for further randomized clinical trials highlighted.

Original Source(s)

Low-Dose Apixaban Cuts Superficial Thrombosis Risk

  • by Andrea Surnit

  • April 2, 2026

Related Content

AGA May Signal Lipids, Female Obesity

Sex-stratified cohort links alopecia to hyperlipidemia in both sexes and obesity in females

Mediterranean Diet Linked to Higher Levels of Mitochondrial Microproteins

Greater adherence was associated with lower oxidative stress markers in older patients.

ACC/AHA Consensus Sets Tricuspid Program Standards

Multisociety document outlines operator, institutional, and registry requirements as transcatheter tricuspid therapies expand